M. Murray

发表

Antiretroviral Treatment Switching and Its Association With Economic Outcomes and Adverse Treatment Effects Among Commercially Insured and Medicaid-Enrolled Patients With HIV in the United States

S. Candrilli, Jennifer S. Korsnes, B. Goodwin, 2016, The Annals of pharmacotherapy.

Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study

M. Murray, M. Ramgopal, J. Mrus, 2019, HIV research & clinical practice.

Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States

M. Markowitz, R. Grant, P. Defechereux, 2018, AIDS and Behavior.

“A dream come true”: Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania

N. Galai, M. Murray, D. Kerrigan, 2020, PloS one.

A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population

M. Murray, A. Chawla, A. de Ruiter, 2018, Infectious Diseases and Therapy.

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

D. Podzamczer, B. Clotet, H. Stellbrink, 2017, The Lancet.

Patient preferences for characteristics of antiretroviral therapies: results from five European countries

B. Gazzard, M. Murray, Shehzad Ali, 2014, Journal of the International AIDS Society.

Patient-Reported Outcomes in the Phase III BRIGHTE Trial of the HIV-1 Attachment Inhibitor Prodrug Fostemsavir in Heavily Treatment-Experienced Individuals

D. Cella, M. Murray, S. Anderson, 2021, The Patient - Patient-Centered Outcomes Research.

Examining adherence barriers among women with HIV to tailor outreach for long-acting injectable antiretroviral therapy

Mardge H. Cohen, A. Adimora, M. Murray, 2020, BMC Women's Health.

Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain

M. Murray, D. Kerrigan, D. Margolis, 2018, PloS one.

Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials

S. Swindells, M. Murray, U. Bredeek, 2020, AIDS and Behavior.

Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial

R. Grant, I. Frank, M. Murray, 2018, HIV clinical trials.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

“It made me more confident that I have it under control”: Patient and provider perspectives on moving to a two-drug ART regimen in the United States and Spain

D. Ward, M. Murray, U. Bredeek, 2020, PloS one.

Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials

S. Swindells, N. Galai, M. Murray, 2021, BMC Health Services Research.

Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks

S. Walmsley, M. Murray, Jenny Huang, 2020, AIDS and Behavior.

“I feel empowered”: women’s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain

S. Swindells, M. Murray, U. Bredeek, 2020, Culture, health & sexuality.

Feasibility of implementing long-acting injectable anti-retroviral therapy to treat HIV: a survey of health providers from the 13 countries participating in the ATLAS-2M trial.

N. Galai, M. Murray, D. Kerrigan, 2020, AIDS research and human retroviruses.